We ask MIT’s Vander Heiden to delineate science from engineering—and NCI from ARPA-H
Conversation with The Cancer Letter

We ask MIT’s Vander Heiden to delineate science from engineering—and NCI from ARPA-H
“The lines are much more blurred in terms of what’s an engineering problem and what’s a basic science problem.”

The boundary between basic science and engineering has been the subject of animated discussions in cancer research for quite some time. Where does science end and engineering begin? Is that boundary porous? How does it shift over time?
Sharpless: ARPA-H and NCI should help each other to “end cancer as we know it”
NCI Director's Report

Sharpless: ARPA-H and NCI should help each other to “end cancer as we know it”

President Joe Biden’s proposed Advanced Research Projects Agency-Health would be a welcome partner to NCI—particularly in conducting large, collaborative clinical investigations, NCI Director Ned Sharpless said.“I think having ARPA-H as part of the NIH is good for the NCI,” Sharpless said April 11 in his remarks at the annual meeting of the American Association for Cancer Research. “How this would fit with the ongoing efforts in cancer at the NCI is still something to work out.”